Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512658 | 0.88 | GRM5 (0.48) | GRM5POLBCYP3A4ALDH1A1MAPT | |
| SCHEMBL513812 | 0.82 | GRM5 (0.45) | GRM5POLBCYP3A4MAPTTP53 | |
| SCHEMBL513546 | 0.82 | GRM5 (0.38) | GRM5POLBCYP3A4ALDH1A1MAPT | |
| SCHEMBL513343 | 0.79 | GRM5 (0.42) | GRM5POLBCYP3A4ALDH1A1MAPT | |
| SCHEMBL514979 | 0.79 | GRM5 (0.48) | GRM5POLBCYP3A4ALDH1A1MAPT | |
| SCHEMBL512866 | 0.79 | GRM5 (0.48) | GRM5POLBCYP3A4ALDH1A1MAPT | |
| SCHEMBL513314 | 0.78 | NPC1 (0.44) | GRM5POLBCYP3A4MAPTMAPK1 | |
| SCHEMBL512243 | 0.76 | GRM5 (0.46) | GRM5POLBCYP3A4ALDH1A1MAPT | |
| SCHEMBL512661 | 0.75 | GRM5 (0.47) | GRM5POLBCYP3A4ALDH1A1MAPT | |
| SCHEMBL512774 | 0.74 | GRM5 (0.45) | GRM5POLBCYP3A4MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | claimed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | claimed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | GRM5 2/4885POLB 2550/4885CYP3A4 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.